Moleculin Biotech is trading 12.26% up now at $0.80, based on the provided live price context; no clear company-specific catalyst has been identified for September 8, 2026.
- The company’s latest listed release was an August 27 investor-conference participation.
- The broader U.S. market is lower, including the Dow at -1.11%, so the gain does not clearly track overall market sentiment.
- Recent clinical, financing, and analyst developments are earlier events, not confirmed catalysts for this move.